시롤리무스

시롤리무스
시롤리무스 구조식 이미지
카스 번호:
53123-88-9
한글명:
시롤리무스
동의어(한글):
시롤리무스
상품명:
Rapamycin
동의어(영문):
SIROLIMUS;RAPAMUNE;RAPA;Sirolomus;Rapamycin/Sirolimus CAS 53123-88-9;Rapamycin from Streptomyces hygroscopicus,23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine, AY 22989, Sirolimus;RPM;BCAR2;TRERF1;CS-440
CBNumber:
CB0275190
분자식:
C51H79NO13
포뮬러 무게:
914.17
MOL 파일:
53123-88-9.mol
MSDS 파일:
SDS

시롤리무스 속성

녹는점
183-185°C
알파
D25 -58.2° (methanol)
끓는 점
799.83°C (rough estimate)
밀도
1.0352 (rough estimate)
증기압
0.56 hPa ( 20 °C)
굴절률
1.5280 (estimate)
인화점
87 °C
저장 조건
-20°C
용해도
에탄올: 가용성2MM
산도 계수 (pKa)
10.40±0.70(Predicted)
물리적 상태
액체
색상
무색~황색
수용성
50mg/ml의 DMSO 또는 25mg/ml의 메탄올에 용해됩니다. 알코올, 디메틸 설폭사이드 및 디메틸 포름아미드에 용해됩니다. 물에 불용성.
감도
Moisture Sensitive/Light Sensitive/Hygroscopic
Merck
14,8114
안정성
2년동안 안정됐나. 구입일로부터 공급된 대로. DMSO 또는 에탄올 용액은 -20°C에서 최대 2개월 동안 보관할 수 있습니다.
CAS 데이터베이스
53123-88-9(CAS DataBase Reference)
안전
  • 위험 및 안전 성명
  • 위험 및 사전주의 사항 (GHS)
위험품 표기 Xi,Xn,F
위험 카페고리 넘버 36/38-36-20/21/22-11
안전지침서 22-24/25-37/39-26-36/37-16
유엔번호(UN No.) UN 1648 3 / PGII
WGK 독일 2
RTECS 번호 VE6250000
자연 발화 온도 301 °C
HS 번호 29349990
유해 물질 데이터 53123-88-9(Hazardous Substances Data)
독성 LD50 in mice (mg/kg): 600 i.p.; >2,500 orally (Vézina)
그림문자(GHS): GHS hazard pictograms
신호 어: Warning
유해·위험 문구:
암호 유해·위험 문구 위험 등급 범주 신호 어 그림 문자 P- 코드
H351 암을 일으킬 것으로 의심됨 (노출되어도 암을 일으키지 않는다는 결정적인 증거가 있는 노출경로가 있다면 노출경로 기재) 발암성 물질 구분 2 경고 P201, P202, P281, P308+P313, P405,P501
예방조치문구:
P201 사용 전 취급 설명서를 확보하시오.
P202 모든 안전 조치 문구를 읽고 이해하기 전에는 취급하지 마시오.
P280 보호장갑/보호의/보안경/안면보호구를 착용하시오.
P308+P313 노출 또는 접촉이 우려되면 의학적인 조치· 조언를 구하시오.
P405 밀봉하여 저장하시오.
P501 ...에 내용물 / 용기를 폐기 하시오.
NFPA 704
2
1 0

시롤리무스 MSDS


Sirolimus

시롤리무스 C화학적 특성, 용도, 생산

화학적 성질

White to Off-White Solid

출처

Rapamycin was first discovered in 1972 in the soil of Easter Island produced by a bacterium called Streptomyces hygroscopicus. It takes its name from Rapa Nui, the indigenous name for the island. It is known clinically as sirolimus or Rapamune.

용도

Labelled Rapamycin. A triene macrolide antibiotic isolated from Streptomyces hygroscopicus. Name derived from the native word for Easter Island, Rapa?Nui. Used as an immunosuppressant; antirestenotic. This compound contains aproximately 2% d0.;Labeled Sir

Indications

Mechanistic target of rapamycin (mTOR) is a serine/threonine-specific protein kinase in the PI3/PI4-kinase family. mTOR was named after the natural macrolide rapamycin, also known as sirolimus, which was isolated from a soil sample from Easter Island in the 1970s and later evaluated as an immunosuppressive agent. The anticancer activity of rapamycin was discovered in the 1980s, although the mechanismof action and the identification of the rapamycin target, mTOR, were not elucidated until the 1990s. Rapamycin and its macrocyclic analogues, such as temsirolimus (Torisel(R), Wyeth/Pfizer) and everolimus (Afinitor(R), Novartis), are grouped as “rapalogs” that constitute the first-generation mTOR inhibitors.
Rapamycin was approved by the US FDA in 1999 as an immunosuppressive agent to prevent organ rejection in patients receiving kidney transplants. Although a large number of clinical studies have been performed to evaluate the anticancer activities of sirolimus in different types of cancers, such as invasive bladder cancer, breast cancer, and leukemia, most studies show limited efficacy. Outside oncological indications, sirolimus was approved by FDA for the treatment of a rare progressive lung disease lymphangioleiomyomatosis in 2015. Temsirolimus was approved for the treatment of advanced RCC. Everolimus was approved in the EU for the prevention of organ rejection in heart and kidney transplant recipients before FDA approved it in 2009 for the treatment of advanced RCC resistant to sunitinib or sorafenib and for the treatment of advanced or metastatic gastrointestinal and lung tumors in 2016. Additionally, rapamycin and rapalogs are being investigated as antiaging therapeutics or for the treatment of age-related diseases. Studies have revealed that mTOR activity can be retained under hypoxic conditions via mutations in the PI3K pathway, leading to increased translation and hypoxic gene expression and tumor progression.

정의

ChEBI: A macrolide isolated from Streptomyces hygroscopicus consisting of a 29-membered ring containing 4 trans double bonds, three of which are conjugated. It is an antibiotic, immunosupressive and antineoplastic agent.

일반 설명

Rapamycin is an anti-fungal antibiotic isolated from Streptomyces hygroscopicus. This antibiotic is active against all strains of Candida albicans. It blocks the signal transduction pathways required for the activation of T-helper cells.

생물학적 활성

Antifungal and immunosuppressant. Specific inhibitor of mTOR (mammalian target of Rapamycin). Complexes with FKBP-12 and binds mTOR inhibiting its activity. Inhibits interleukin-2-induced phosphorylation and activation of p70 S6 kinase.

시롤리무스 준비 용품 및 원자재

원자재

준비 용품


시롤리무스 공급 업체

글로벌( 844)공급 업체
공급자 전화 이메일 국가 제품 수 이점
Shanghai Minbiotech Co., Ltd.
+8617315815539
sales@minbiotech.com CHINA 129 58
Hangzhou Benoy Chemical Co., Ltd
+8617342059697
sales@benoychem.com China 315 58
Hebei Lingding Biotechnology Co., Ltd.
+86-18031140164 +86-19933155420
erin@hbldbiotech.com China 878 58
Seasons Biotechnology Co., Ltd.
+86-0576-89232655 +86-13566878689
info@seasonsbio.com China 46 58
Guangzhou Tengyue Chemical Co., Ltd.
+86-86-18148706580 +8618826483838
evan@tyvovo.com China 152 58
BOC Sciences
+16314854226
inquiry@bocsci.com United States 19743 58
Hebei Mojin Biotechnology Co., Ltd
+8613288715578
sales@hbmojin.com China 12456 58
Henan Tengmao Chemical Technology Co. LTD
+8615238638457
salesvip2@hntmhg.com China 415 58
Hangzhou ICH Biofarm Co., Ltd
+undefined8613073685410
sales@ichemie.com China 985 58
Shaanxi Haibo Biotechnology Co., Ltd
+undefined18602966907
qinhe02@xaltbio.com China 1000 58

시롤리무스 관련 검색:

Copyright 2019 © ChemicalBook. All rights reserved